• Łukasz Wołowiec, Daniel Rogowicz, Jacek Budzyński, Joanna Banach, Anna Wołowiec, Mariusz Kozakiewicz, Maciej Bieliński, Albert Jaśniak, Joanna Osiak, and Grzegorz Grześk.
• Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland.
• Ann. Med. 2024 Dec 1; 56 (1): 23053092305309.

BackgroundThis is the first study to examine the clinical utility of measuring plasma secretoneurin (SN) levels in patients with heart failure with reduced ejection fraction (HFrEF), as a predictor of unplanned hospitalization, and all-cause mortality independently, and as a composite endpoint at one-year follow-up.MethodsThe study group includes 124 caucasian patients in New York Heart Association (NYHA) classes II to IV. Plasma SN concentrations were statistically analyzed in relation to sex, age, BMI, etiology of HFrEF, pharmacotherapy, clinical, laboratory and echocardiographic parameters. Samples were collected within 24 h of admission to the hospital.Key ResultsIn the 12-month follow-up, high SN levels were noted for all three endpoints.ConclusionsSN positively correlates with HF severity measured by NYHA classes and proves to be a useful prognostic parameter in predicting unplanned hospitalizations and all-cause mortality among patients with HFrEF. Patients with high SN levels may benefit from systematic follow-up and may be candidates for more aggressive treatment.

11 keywords...

hide…